UY29020A1 - Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.- - Google Patents

Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.-

Info

Publication number
UY29020A1
UY29020A1 UY29020A UY29020A UY29020A1 UY 29020 A1 UY29020 A1 UY 29020A1 UY 29020 A UY29020 A UY 29020A UY 29020 A UY29020 A UY 29020A UY 29020 A1 UY29020 A1 UY 29020A1
Authority
UY
Uruguay
Prior art keywords
difenylamine
derivatives
saliciltiazoles
procedures
replaced
Prior art date
Application number
UY29020A
Other languages
English (en)
Inventor
Dr Stefan Petry
Dr Karl-Heinz Baringhaus
Dr Norbert Tennagels
Dr Gunter Muller
Dr Reinhard Kirsch
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of UY29020A1 publication Critical patent/UY29020A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a saliciltiazoles sustituídos con difenilamina o derivados de difenilamina y a sus sales fisiológicamente toleradas. Los compuestos son apropiados, por ejemplo, como medicamentos para reducir la glucosa en sangre y para la prevención y el tratamiento de diabetes.
UY29020A 2004-07-17 2005-07-15 Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.- UY29020A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004034697A DE102004034697A1 (de) 2004-07-17 2004-07-17 Mit Diphenylamin oder Diphenylaminderivaten substituierte Salicylthiazole, Verfahren zu deren Herstellung und deren Verwendung

Publications (1)

Publication Number Publication Date
UY29020A1 true UY29020A1 (es) 2006-02-24

Family

ID=34971604

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29020A UY29020A1 (es) 2004-07-17 2005-07-15 Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.-

Country Status (21)

Country Link
US (1) US7741491B2 (es)
EP (1) EP1771426B1 (es)
JP (1) JP2008506643A (es)
KR (1) KR20070043787A (es)
CN (1) CN100582098C (es)
AR (1) AR049588A1 (es)
AT (1) ATE381551T1 (es)
AU (1) AU2005263418A1 (es)
BR (1) BRPI0513423A (es)
CA (1) CA2574162A1 (es)
DE (2) DE102004034697A1 (es)
DK (1) DK1771426T3 (es)
ES (1) ES2296199T3 (es)
HK (1) HK1104534A1 (es)
IL (1) IL180570A0 (es)
MX (1) MXPA06014443A (es)
PE (1) PE20060554A1 (es)
PT (1) PT1771426E (es)
TW (1) TW200616985A (es)
UY (1) UY29020A1 (es)
WO (1) WO2006007959A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
EP1446110A2 (en) * 2001-10-16 2004-08-18 Structural Bioinformatics Inc. Organosulfur inhibitors of tyrosine phosphatases
CA2469228A1 (en) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
EP1510207A4 (en) * 2002-06-05 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC MEDICAMENT AGAINST DIABETES

Also Published As

Publication number Publication date
CA2574162A1 (en) 2006-01-26
IL180570A0 (en) 2007-06-03
AR049588A1 (es) 2006-08-16
EP1771426B1 (de) 2007-12-19
PT1771426E (pt) 2008-01-31
US7741491B2 (en) 2010-06-22
DE102004034697A1 (de) 2006-02-09
HK1104534A1 (en) 2008-01-18
US20070191441A1 (en) 2007-08-16
ATE381551T1 (de) 2008-01-15
EP1771426A1 (de) 2007-04-11
JP2008506643A (ja) 2008-03-06
DK1771426T3 (da) 2008-05-05
ES2296199T3 (es) 2008-04-16
AU2005263418A1 (en) 2006-01-26
PE20060554A1 (es) 2006-06-24
TW200616985A (en) 2006-06-01
DE502005002310D1 (de) 2008-01-31
KR20070043787A (ko) 2007-04-25
CN100582098C (zh) 2010-01-20
CN1989116A (zh) 2007-06-27
WO2006007959A1 (de) 2006-01-26
MXPA06014443A (es) 2007-03-21
BRPI0513423A (pt) 2008-05-06

Similar Documents

Publication Publication Date Title
UY29020A1 (es) Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.-
UY29258A1 (es) Ácidos hidroxibifenilcarboxílicos y derivados, procedimientos para prepararlos y su uso
PA8635301A1 (es) Derivados sustituidos del dioxido de oxazolbenzoisotiazol, procedimiento para su preparacion y su uso
UY28443A1 (es) Derivados sustituidos del dióxido de tiazol-benzoisotiazol, procedimiento para su preparación y su uso.
UY28732A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparación y su uso como medicamentos.
UY28726A1 (es) N-ciclohexilimidazolinonas sustituidas.procedimientos para su preparación y su uso como medicamentos.
UY31351A1 (es) (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos
NI200800217A (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos.
PA8841701A1 (es) Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden compuestos y su uso
GT200500307A (es) Compuestos quimicos
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
GT200600426A (es) Formulacion novedosa
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
UY28870A1 (es) Derivados heterocíclicos, composiciones y proceso de preparación
CL2008002424A1 (es) Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido; y uso de la composicion farmaceutica para el tratamiento de la diabetes mellitus, tolerancia anormal a la glucosa e hiperglucemia, trastornos metabolicos, entre otras.
UY30165A1 (es) Nuevas arildihidroisoquinolinonas sustituidas con aminolcoholes, procedimiento para su preparación y su uso como medicamentos
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
CR11057A (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos
CL2023000087A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
UY30046A1 (es) Nuevos derivados de furopirimidina acíclicos sustitiudos y su uso
CL2021002397A1 (es) Derivados de insulina sensibles a la glucosa
UY28209A1 (es) Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos.
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones